Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
52.11
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
52.11
Bid (Size)
52.50 (20)
Ask (Size)
57.21 (1)
Prev. Close
52.11
Today's Range
52.11 - 52.11
52wk Range
32.83 - 57.09
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
August 05, 2024
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
August 04, 2024
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!
Via
InvestorPlace
Performance
YTD
+39.37%
+39.37%
1 Month
-0.84%
-0.84%
3 Month
+27.53%
+27.53%
6 Month
+54.72%
+54.72%
1 Year
+24.04%
+24.04%
More News
Read More
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
August 01, 2024
Via
Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
August 01, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
Via
Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
Via
Investor's Business Daily
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
July 22, 2024
Via
Chartmill
NASDAQ:HALO is showing good growth, while it is not too expensive.
July 18, 2024
Via
Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
July 16, 2024
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
July 18, 2024
Via
InvestorPlace
Biotech Arvinas Stock Earns 82 RS Rating
July 17, 2024
Via
Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
July 16, 2024
Via
Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
July 15, 2024
Via
InvestorPlace
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
July 15, 2024
Via
Chartmill
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
July 12, 2024
Via
Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
July 09, 2024
Via
Chartmill
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
June 24, 2024
Via
Benzinga
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
June 24, 2024
Via
Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Via
InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
July 01, 2024
Via
InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
June 26, 2024
Via
Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
June 24, 2024
Via
Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
June 20, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.